Among new molecules on the horizon for the treatment of overweight and obesity, the most promising appears to be tirzepatide (LY3298176), an incretin mimetic with a dual action targeting both the GLP1 receptor and the glucosedependent insulinotropic polypeptide (GIP) receptor 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 (Figure 2 and Supplementary Figure 1)
300,000 deaths from resistant infections later, we're still paying for it
A typical starting dose is one tablet per day, which can be gradually increased to four tablets per day
Once-daily oral use: It is taken as a tablet once daily, making it more convenient than injectable GLP-1 medicines
2 In clinical trials, permanent discontinuation of treatment due to adverse reactions was similar in patients treated with Wegovy HD and Wegovy 2.4 mg injection (Wegovy HD 5%, Wegovy 2.4 mg 5%, placebo 2%)